Chemung Canal Trust Co. Has $16.73 Million Position in Johnson & Johnson (JNJ)
Chemung Canal Trust Co. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,426 shares of the company’s stock after selling 1,621 shares during the period. Johnson & Johnson makes up 3.9% of Chemung Canal Trust Co.’s holdings, making the stock its 3rd largest position. Chemung Canal Trust Co.’s holdings in Johnson & Johnson were worth $16,725,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of the stock. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at $3,220,322,000. State Street Corp raised its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in Johnson & Johnson during the fourth quarter valued at $277,294,000. Fiera Capital Corp raised its stake in Johnson & Johnson by 16.9% in the fourth quarter. Fiera Capital Corp now owns 4,249,504 shares of the company’s stock valued at $489,585,000 after buying an additional 615,219 shares during the period. Finally, Korea Investment CORP raised its stake in Johnson & Johnson by 38.9% in the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after buying an additional 596,134 shares during the period. 66.06% of the stock is currently owned by institutional investors.
Johnson & Johnson (JNJ) traded up 0.01% during trading on Friday, reaching $133.10. The company had a trading volume of 4,270,571 shares. The stock has a 50 day moving average price of $133.09 and a 200 day moving average price of $126.30. The firm has a market capitalization of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the previous year, the company posted $1.74 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio is 56.76%.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/chemung-canal-trust-co-has-16-73-million-position-in-johnson-johnson-jnj/1479817.html.
JNJ has been the topic of several research reports. J P Morgan Chase & Co raised Johnson & Johnson from a “neutral” rating to an “overweight” rating and upped their target price for the company from $123.64 to $140.00 in a report on Monday, May 15th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. UBS AG reissued a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 target price on the stock. in a report on Monday, May 15th. Finally, BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Wednesday, April 19th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $133.72.
In other news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.